Ana María
López González
Hospital Severo Ochoa
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Severo Ochoa (1)
2019
-
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study
Breast Journal, Vol. 25, Núm. 2, pp. 219-225